Most Recent
Nine has won its legal challenge to orders that would have forced it to hand over a draft version of a 60 Minutes episode and restricted it from airing the program after an appeals court found a judge had no power to make the orders.
Regenerative medicine company Mesoblast has been hit with a second class action for allegedly misleading shareholders about it Remestemcel-L treatment for COVID-19 complications.
Philips Electronics has been fined $133,200 for failing to provide timely notice to the country's health regulator of deterioration in its sleep machines, after being hit with a class action lawsuit over degrading foam in the devices.
Settlement talks in a class action on behalf of women injured by allegedly defective pelvic mesh products have failed after Astora Health took a long-standing $27 million settlement offer off the table.
The Full Federal Court has rejected an Australian inventor’s appeal of a ruling that found three manufacturers of essential oil products did not infringe his patent because the oil was a “staple commercial product”.
The New South Wales government has pushed to consolidate a class action accusing it of failing to pay overtime hours to junior doctors with multiplying industrial actions filed by Australian Salaried Medical Officers' Federation.
Victoria’s Emergency Services Telecommunications Authority may be hit with a class action over alleged systemic failures in its ambulance call handling operations that may have led to at least 15 deaths.
An IP Australia delegate has rejected German drug maker Ever Neuro Pharma's claim that extensive experimental evidence was needed to prove the usefulness of a Parkinson's drug developed by UK-based Britannia Pharmaceuticals.
The applicants in a class action against The Cosmetic Institute and twelve doctors over allegedly "incompetent" breast augmentation surgery have won court approval to expand their case to allege misleading and deceptive conduct and breaches of the consumer guarantees in the Australian Consumer Law.
Regenerative medicine company Mesoblast is facing another class action over claims it misled shareholders about the potential application of a developmental stem cell product to treat terminally ill children.